Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer

E-ISSN： 1875-5607|13|6|915-920

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.13, Iss.6, 2013-05, pp. : 915-920

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Which drug combination for hormone-refractory prostate cancer?

By Doggrell Sheila A

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 4, 2005-04 ,pp. : 667-670

Informa Healthcare

Access to resources Recommend Favorite

Novel Biological Agents for the Treatment of Hormone-Refractory Prostate Cancer (HRPC)

Current Medicinal Chemistry, Vol. 12, Iss. 3, 2005-02 ,pp. : 277-296

Bentham Science Publishers

Access to resources Recommend Favorite

Docetaxel: In Hormone-Refractory Metastatic Prostate Cancer

By McKeage Kate Keam Susan J.

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2287-2294

Adis International

Access to resources Recommend Favorite

Docetaxel in Hormone-Refractory Metastatic Prostate Cancer: A Viewpoint by William R. Berry

By Berry William R.

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2295-2297

Adis International

Access to resources Recommend Favorite

Treatment Options in Hormone-Refractory Prostate Cancer: Current and Future Approaches

By Harris K.A. Reese D.M.

Drugs, Vol. 61, Iss. 15, 2001-01 ,pp. : 2177-2192

Adis International

Access to resources Recommend Favorite